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OBJECTIVES: To analyze the association between costs of
illness and degree of obesity for a population-based sample of
German adults. METHODS: In a cross-sectional resident popu-
lation survey in the KORA study region of Augsburg, Germany
(random sampling, N = 947, age: 25–74 years), body mass index
(BMI) was assessed anthropometrically and categorized into
normal weight (18.5 £ BMI < 25), preobese (25 £ BMI < 30),
obese class 1 (30 £ BMI < 35) and obese classes 2–3 (BMI ≥ 35).
Health care utilization and inability to work were assessed by
self-reports via three computer-aided telephone interviews over
six months. For drugs, actual prices were used; for all other
direct cost components, costs were calculated by imputing mean
unit costs on the reported resource consumption ﬁgures. Indirect
costs (productivity loss due to temporary inability to work) were
valued by individual gross earnings. Multivariate regression
models were used to estimate the effect of BMI on direct and
indirect costs of illness, while controlling for age, sex, social
status, and urban vs. rural place of residence. RESULTS: Com-
pared with persons of normal weight, obesity class 1 (obesity
classes 2–3) was associated with 39% (63%) higher costs of
visits to general practitioners, 51% (388%) higher costs of inpa-
tient hospital care, and 19% (136%) higher costs of drug uti-
lization. Higher drug expenditures for male obese adults were
particularly due to diseases of the alimentary tract and metabo-
lism and diseasesof the musculoskeletal system, and for female
obese adults due to diseases of the cardiovascular system. Alto-
gether, yearly per capita costs of illness (direct plus indirect) in
these 3 groups added up to €2116€ (95% CI €1427–€2805),
€2643 (95% CI €1848–€3438), and €5453 (95% CI
€4102–€6803). CONCLUSIONS: Results point to a consider-
able economic impact of obesity, especially obesity classes 2–3.
The lesson for health care research is that obesity class 1 and
obesity classes 2–3 should be analyzed separately.
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OBJECTIVES: Obesity among children has developed into a
major public health problem in Germany. In 1999 15% of chil-
dren aged 14–17 years were obese and approximately 1% of
these were diabetics. Obesity and T2DM are important causes
of morbidity among young people associated with high costs for
the health system. The objective of this paper is to estimate the
economic burden of illness of obesity and T2DM of children and
adolescents in Germany. METHODS: Cost calculations are
based on the top down approach and the prevalence method.
Direct costs of illness are derived from aggregate statistical data
and various scientiﬁc publications. Included are costs of hospi-
talization (ICD 10: obesity E 65–67; T2DM E 11), costs of reha-
bilitation and costs of special medical programs for obese
children. Other direct costs (as e.g. costs of remedies and aids or
costs of drugs) could not be included due to a lack of data; 
the same holds for indirect costs. Except for T2DM, co-mor-
bidities of obesity are neglected in this analysis. RESULTS:
During 1999–2003 the mean direct costs of obesity per year were
€58.3 million with €51.8 million for rehabilitation, €3.2 million
for hospital care and €3.3 million for special medical programs.
The costs of juvenile T2DM were €0.7 million (hospital care).
Mean costs per treated obese child added up to €3540 and to
€5720 per treated obese child with T2DM. CONCLUSION:
Obesity and T2DM are rapidly emerging as major disorders of
childhood and adolescence and as important cost drivers for the
health system. There is a need for further research in costs of
obesity and T2DM of children and for studies on intervention
to obviate a major public health crisis in Germany. The challenge
for health policy is to identify effective and efﬁcient prevention
strategies.
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OBJECTIVE: To identify the impact of bariatric surgery on health
outcomes and pharmacological treatment among obese patients.
METHODS: A comprehensive analysis of 833 patients with a
diagnostic of obesity (ICD-9-CM = 278) with a CPT code of
bariatric surgery (43,659, 43,842, 43,843, 43,846, 43,847,
43,999, S2085) was performed. The sample was drawn from a
US administrative claims database covering 2.2 million lives.
Diagnostics and pharmacological treatment were compared in the
180 days preceding the surgery and days 30–210 following the
surgery. Frequency counts were performed on diagnostics using
aggregated 3 digit ICD-9-CM codes and pharmacological treat-
ment using AHFS (American Hospital Formulary Service) thera-
peutic classes. Pre- and post surgery frequencies were compared
using chi-squared tests. RESULTS: Among the 833 patients (mean
age = 42.3, 15.1% male), cardiovascular disease was cut by half
(from 47.5% to 23.9%), diabetes mellitus was reduced from
18.0% to 12.9%, and respiratory disease in general was reduced
from 57.7% to 14.8% while asthma in particular dropped from
11.2% to 3.7%. Diseases of the joints and muscles were reduced
from 36.6% to 24.0%. Psychiatric disorders fell from 18.4% to
9.7%. On the contrary, anemia diagnoses increased from 4.1%
to 13.6%. The frequency of pharmacological treatment for the
conditions identiﬁed above fell dramatically often to a greater
extent than the reduction in the prevalence of the underlying con-
dition. The percentage of patients receiving insulin treatment and
oral antidiabetics decreased from 5.2% to 2.2% and from 12.7%
to 4.3%, respectively. The proportion of patients receiving treat-
ment for cardiovascular diseases (Ace inhibitors, calcium channel
blockers, diuretics, betablockers, and other hypotensives) fell
from 39.3% to 26.1%. Antiacid use also dropped from 26.8%
to 22.2%. All differences between pre- and post surgery propor-
tions are statistically signiﬁcant (P = 0.05). CONCLUSION:
Bariatric surgery is associated with signiﬁcant improvements in
health outcomes and reduced pharmacological utilization for
major disease categories.
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